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Background: The heterogeneity of malaria transmission makes widespread elimination a difficult goal to achieve.
Most of the current vector control measures insufficiently target outdoor transmission. Also, insecticide resistance
threatens to diminish the efficacy of the most prevalent measures, indoor residual spray and insecticide treated
nets. Innovative approaches are needed. The use of endectocides, such as ivermectin, could be an important new
addition to the toolbox of anti-malarial measures. Ivermectin effectively targets outdoor transmission, has a novel
mechanism of action that could circumvent resistance and might be distributed over the channels already in place
for the control of onchocerciasis and lymphatic filariasis.
Methods: The previous works involving ivermectin and Anopheles vectors are reviewed and summarized. A
review of ivermectin’s safety profile is also provided. Finally three definitive clinical trials are described in detail
and proposed as the evidence needed for implementation. Several smaller and specific supportive studies are
also proposed.
Conclusions: The use of ivermectin solves many challenges identified for future vector control strategies. It is
an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies
suggest it might become an effective and complementary strategy in malaria elimination and eradication
efforts; however, intensive research will be needed to make this a reality.
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The last 15 years have seen renewed efforts towards con-
trolling malaria-associated morbidity and mortality, elimi-
nating malaria from endemic regions and even planning
eventual eradication. For these efforts, several research
agendas have been developed [1,2]. However, the gains in
malaria control over the last decade are severely threatened
by widespread insecticide resistance in vectors [3,4] and
emerging artemisinin-resistant Plasmodium falciparum
[5,6]. These threats pose a major challenge to the vision of* Correspondence: cchaccour@unav.es; Brian.Foy@ColoState.EDU
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reproduction in any medium, provided the orthe Roll Back Malaria Partnership whereby malaria is no
longer a major cause of mortality by 2015 [7]. Global mal-
aria eradication will require new tools and the implementa-
tion of an integrated approach targeting the vector and
parasite in the ever changing human reservoir [1,8].
Vector control has traditionally been the mainstay of
malaria control in the past and is certain to remain so.
The Malaria Eradication (malERA) Consultative Group
on Vector Control has identified three main challenges
to developing vector-targeted interventions that support
elimination and eradication goals [9]. The first challenge
is developing a broader range of insecticides with novel
modes of action to counter current insecticide resistance
among Anopheles species [10]. Secondly, to develop con-
trol methods that affect outdoor feeding and resting vec-
tors; the current most effective tools, indoor residualral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(LLINs), do little to prevent outdoor transmission from
these vectors and can even drive exophagy and exophily
among them [11]. Lastly, new interventions are needed
to reduce the extremely high vectorial capacities of mal-
aria vectors in sub-Saharan Africa [12].
A potential new tool
Endectocides are drugs that have activity against endopara-
sites (mainly parasitic nematodes) and ectoparasites, (they
can kill arthropods that blood-feed on a treated subject).
Ivermectin is the only known endectocide currently ap-
proved for human use. It is a semi-synthetic derivate from
the fermentation products of Streptomyces avermectinius
[13]. Ivermectin primarily agonizes glutamate-gated chlo-
ride channels in invertebrates, causing flaccid paralysis and
death [13]. Glutamate-gated chloride channels do not exist
in humans and other weakly sensitive channels are found
in the human central nervous system, where the blood–
brain barrier limits drug access [14]. These characteristics
explain ivermectin’s excellent safety profile (see below).
Ivermectin is one of the few drugs used in human mass
drug administration (MDA) campaigns, and more than one
billion treatments have been delivered over the last 25 years
for controlling onchocerciasis and lymphatic filariasis [15].
Anopheles mosquitoes are particularly sensitive to
very low concentrations of ivermectin relative to other
vectors examined [16-18], thus offering promise for
malaria control. The methods used to examine ivermec-
tin’s effects on Anopheles have been diverse (Table 1),
including in vitro membrane feeding, direct blood feed-
ing on treated animals or humans [19,20], and wild
mosquito collections after they have fed on humans re-
ceiving ivermectin MDA [21-23]. These studies clearly
show that ivermectin is toxic to all Anopheles species
examined, and at concentrations found in human blood
after treatment.
Ivermectin addresses the three main challenges identi-
fied by the malERA vector control group [9]: (1) its mode
of action is different from the four currently used insecti-
cides for malaria vector control, thus it likely could cir-
cumvent the issue of emerging insecticide resistance; (2)
as a systemic drug, it is ingested by all biting mosquitoes
and so it will equally target indoor and outdoor-biting
mosquitoes, as well as those with crepuscular activity; and,
(3) the activity of the drug targets four out of the five
variables of vectorial capacity [33,34], especially the
most influential variable, the daily probability of mos-
quito survival. Ivermectin also fits many of the ideals
identified in the malERA initiative, including integra-
tion with the current vector control tools, any behav-
ioural adaptation away from biting treated humans
would only be beneficial, and it is expected to affect
vector population structure [35].Ivermectin’s safety
The onchocerciasis control programme
The French authorities approved ivermectin for human
use in 1987. Soon after, Merck & Co Inc. decided to donate
ivermectin for onchocerciasis control and the MectizanW
Donation Program was created [13]. Since then, more
than a 1.5 billion treatments have been distributed in
Africa and Latin America for onchocerciasis control and
another 665 million for treatment of lymphatic filariasis
[15]. In this context, adverse events (AE) to ivermectin
have been usually mild, transient, associated with intensity
of microfilarial infection and primarily characterized as
mild Mazzoti-type reactions to dying microfilaria [36]. No
significant association has been found between ivermectin
plasma levels and AE [37].
Loa loa
The limited number of severe neurological AE seen with
ivermectin use, include encephalopathy and coma after
ivermectin administration to patients who were infected
with Loa loa. These reactions are closely related to the
microfilarial load and are due to parasite lysis rather than
drug toxicity [38]. Rapid assessment of loasis is now
recommended before ivermectin MDA in Loa-endemic
areas [39].
Higher or multiple doses
Several authors have evaluated the safety and tolerability
of ivermectin at doses different than those indicated.
Duke et al. [40] gave adult volunteers six fortnightly
doses of 100 μg/kg without observing severe AE. Awadzi
et al. [41] found no difference with controls in tolerance
and early AE using doses of up to 800 μg/kg. Guzzo
et al. [42] found no significant CNS toxicity or AE in
healthy volunteers taking either a single high dose of up to
2,000 μg/kg or repeated doses (three in a week) of up to
1,091 μg/kg. Kamgno et al. [43] randomized Onchocerca-
infected volunteers to different treatment schemes and
one group received 800 μg/kg every three months for
three years (accumulated dose of 8,950 μg/kg), but repor-
ted that all groups had comparable rates of AE. The high
dose group reported transitory mild and subjective visual
side effects more often (blurring of vision, changes in
colour vision, etc.), but ophthalmological examinations re-
vealed no structural explanation.
Children, pregnancy and lactation
Ivermectin is now licensed for the treatment of children
weighing more than 15 kg [44].
Pacque et al. [45] carried out a prospective study
in Liberia, where 14,000 people received the drug at
150 μg/kg. Out of some 4,000 women treated, 200 were
inadvertently treated during pregnancy. No significant
differences in birth defect rates, development status or
Table 1 Studies evaluating Anopheles mosquito mortality and Plasmodium transmission after imbibing blood
containing ivermectin
Reference Methods Species Results
Pampiglione 1985
[24]
Feeding on impregnated cotton
and on treated mice.
An. stephensi Increased mortality in all groups feeding on impregnated
cotton, 100% mortality in those feeding at 28,000 μg/L.
Dose: 140–28,000 μg/kg
(once, subcutaneous)
100% mortality 24-hr post feeding on mice treated at dose
≥2,800 μg/kg. Increased mortality in all other dose-groups.
Iakubovich 1989
[25]
Membrane and feeding on treated rabbits.
Dose: 340 μg/kg (once, subcutaneous)
An. stephensi Death rates among An. stephensi fed on rabbits 4, 5 and
6 days after administration of the drug were 93, 70 and
79%, respectively.
An. atroparvus No difference with control seen in An. sacharovi and
An. atroparvus.An. sacharovi
Jones 1992 [26] Membrane and feeding on treated dogs
Dose: 10–2,500 μg/kg (once, orally)
An. quadrimaculatus Mortality ≥90% in all but one treatment groups 24-hr post
blood feeding and ≥90% in all groups 48-hr post blood feeding
Gardner 1993 [27] Feeding on treated dogs An. quadrimaculatus Significant increase in mortality. LD50 = 9.9 μg/kg [6.0, 13.8]
Dose: 6–24 μg/kg (once, orally) Significant decrease in oviposition and egg-hatching from
survivors
Bockarie 1999 [21] Field collections of engorged females
before and after MDA for lymphatic filariasis
An. punctulatus Significant decrease in 9-day cumulative survival rate of
Anopheles spp. collected 1–3 days post-treatment (0%)
vs those collected pre-treatment (67%)Dose: 400 μg/kg ivermectin +/− 6 mg/kg DEC
(once, orally) An. koliensis The 48-hr survival rate of An. puctulatus collected from two
houses in the a treated village the morning following MDA
was 31% vs 94% from two houses of an untreated village
Pre- and post-treatment all-night landing catches showed
no significant reduction in human biting rates.
Foley 2000 [20] Feeding on one treated human volunteer
Dose: 250 μg/kg (once, orally)
An. farauti 12-day cumulative mortality rate of mosquitoes was 100%,
95%, 93%, and 40% for those fed 0, 7, 10 and 14 days
post-treatment vs 10% for those fed pre-treatment
Fritz 2009 [28] Membrane and feeding on treated cattle An. gambiae Membrane feeding: LC50 for An. gambiae s.l. was 19.8 ± 2.8
ppb; no oviposition from mosquitoes fed on >10 ppbDose: 600 μg/kg (once, subcutaneously)
An. arabiensis Cattle feeding: Total cumulative survival of An. gambiae s.s.
significantly different from controls when fed up to 20 days
post-treatment; no or significantly reduced oviposition
when fed up to 17 days post-treatment
Chaccour 2010
[19]
Feeding on randomized, treated volunteers
and controls
Mean 12-day survival time of 2.38 days [1.52, 3.24] for
mosquitoes fed on treated subjects at 1 day post-treatment vs
5.52 days [4.65, 6.4] for mosquitoes fed on untreated control
subjects
Dose: 200 μg/kg (once, orally)
An. gambiae No effect on mosquitoes fed on treated subjects at 14 days
post-treatment
Kobylinski 2010
[16]
membrane feedings
Dose: NA
An. gambiae LC50 = 22.4 ng/ml [18.0, 26.9]. At sub-lethal concentrations,
significantly reduced mosquito re-blood feeding rates and
a second ivermectin blood meal, even at a decreased
concentration, further increased mortality
Sylla 2010 [23] Field collections of engorged females before
and after MDA for onchocerciasis
An. gambiae 5-day cumulative survival of An. gambiae s.s. was significantly
reduced from 3 treated villages vs pair-matched control villages
Dose: 150 μg/kg (once, orally) An. arabiensis An. gambiae s.s. captured in treated villages 1–6 days post-
treatment had significantly reduced survival v those caught
pre-MDA and those caught >7 days post-treatment
Kobylinski 2011
[22]
Field collections of engorged females
before and after MDA for onchocerciasis
An. gambiae For 12 days after the MDA, mean P. falciparum sporozoite rate
was significantly reduced by 79% in 3 replicate treated villages
while it increased by 246% in pair-matched control villagesDose: 150 μg/kg (once, orally)
Butters 2012 [29] Membrane feeding
Dose: NA
An. gambiae Sub-lethal concentrations (LC25 & LC5) caused significant
knockdown and reduced recovery rates
Fritz 2012 [30] Membrane feeding
Dose: NA
An. arabiensis LC50 = 7 · 9 ppb [6.2, 9.9]; oviposition among survivors
was significantly reduced at ≥7 ppb
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Table 1 Studies evaluating Anopheles mosquito mortality and Plasmodium transmission after imbibing blood
containing ivermectin (Continued)
Bastiaens 2012
[31]
Feeding on treated Swiss mice, Wistar
rats and Cynomolgus monkeys
Dose: 200–400 μg/kg
(different intervals, orally)
An. stephensi 3-day cumulative mortality of mosquitoes fed on treated
mice, rats and monkeys significantly differed from controls
when fed up to 2, 4 and 3 days post-treatment, respectively
Kobylinski 2012
[32]
Membrane feeding An. gambiae Sub-lethal concentrations significantly inhibited P. falciparum
sporogony when fed prior to, concurrent with, and 6 and
9 days after infection with gametocytes
Dose: NA
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treated mothers in the same population. These findings
have been confirmed in hundreds of women in North
Cameroon [46], Mali [47], Ghana [48] and Uganda [49].
Thus, pregnant women in onchocerciasis-endemic areas
at high risk of loss of sight are no longer excluded from
ivermectin treatment [50].
Ivermectin levels in human breast milk are low. After
a single oral dose of 150 μg/kg in healthy women,
Ogbuokiri et al. [51] found peak levels of 14.13 +/− 0.43
ng/ml after 6.5 hours. Therefore, a breast-fed new born
would get a dose of only 2.75 μg/kg. It is no longer
recommended to exclude nursing women during MDA
of Mectizan in onchocerciasis-endemic areas [50].
Applying ivermectin for malaria control
As suggested in the publications in Table 1, and by pre-
vious modelling exercises [20,23,35] there are several
theoretical ways that ivermectin might be applied to help
control malaria:
1) In ongoing onchocerciasis and lymphatic filariasis
control campaigns, a single dose of ivermectin is
administered to entire villages on a single day during
MDA, with coverage rates generally between 60-80%.
This has positive collateral effects against soil-
transmitted helminthes, [52] and ectoparasites.
After MDA, most villagers’ blood is toxic to biting
Anopheles and this effect may last for approximately
six days [23]. These toxic blood meals can kill most
of the infectious adult mosquitoes, and while the
numbers of adult Anopheles feeding on people can
rebound quickly depending on the larval reservoir,
the new population is young and most have not
lived long enough to bite a gametocytaemic person
and become infectious (the minimum time required
for P. falciparum to develop in the vector is nine
days). Thus, sporozoite transmission can be
suppressed for weeks after MDA [22]. In this way,
ivermectin MDA might be ideal to stem malaria
epidemics, to interrupt brief transmission seasons
or offer sustained transmission reduction if given
repeatedly over longer transmission periods.2) Recent publications have highlighted the likely
benefit of combining ivermectin with drugs such as
artemisinin combination therapy (ACT). ACT is
highly effective in most malaria-endemic settings but
does not prevent malaria-transmission in the first
weeks after treatment [53,54]. ACT in combination
with ivermectin may be an effective option for anti-
malarial MDA where residual transmission potential
is a major concern [55,56] and where mass
screening and treatment (MSAT) or drug
combinations fulfilling the single encounter radical
cure and prophylaxis (SERCaP) profile [57] are
alternative possibilities. Ivermectin would be an
additive, blocking onward transmission of parasites
from treated individuals by killing most Anopheles
biting the person and inhibiting Plasmodium
development in any surviving vectors. This would be
especially important to stem the spread of resistant
P. falciparum and a safe alternative for or in
addition to gametocytocidal drugs [58].
3) Treatment of peridomestic animals in areas where
Anopheles mosquitoes exhibit both zoophagic and
anthropophagic behaviour [30], not only with
ivermectin but with other classes of systemic
endectocides approved for veterinary use, is expected
to control the vector population size by increasing
mortality, reducing fertility and flying capacity and
may have further effects on transmission by inhibiting
sporogony in the surviving vectors.Definitive studies
Before ivermectin can be recommended for malaria con-
trol, large-scale community trials must be conducted to
provide definitive evidence of its role in malaria control.
Below are what is envisioned as the three primary trials
required:
1) Single or repeated human ivermectin MDA for malaria
control
Design: placebo-controlled, cluster-randomized, double-
blind trial.
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to clusters (villages) over a non-continuous malaria
transmission season (e g, the rainy season) at the doses
and frequency determined by previous studies.
Entomological measures:
– Mosquito survival
– Mosquito population structure
– Mosquito immigration into clusters
– Entomological inoculation rate
– Vectorial capacity
Parasite measures:
– Sporozoite rates (mosquitoes)
– Plasmodium prevalence through periodic cross-
sectionals
– Molecular force of infection
– NTD and ectoparasite prevalence and intensity
Clinical measures:
– Malaria clinical disease incidence as detected by
passive case detection
– Serological markers of mosquito bite exposure [59,60]
– Anaemia prevalence
– Adverse events incidence
2) Comparison treatment of ivermectin vs ivermectin +
ACT
Design: individual-randomized, double-blind trial.
Methods: confirmed cases or asymptomatically infected
individuals are enrolled in ACT and ivermectin +ACT
arms. Doses and frequency determined by previous studies
Entomological measures:
– Colony mosquito survival and recovery after feeding
directly or indirectly on blood of treated subjectsParasite measures:
– Sporogony assessment in fed mosquitoes
– Plasmodium clearance and rate
– Gametocyte carriage and infectiousness
Clinical measures:
– Safety and toxicology (blood chemistry,
haemoglobin, AEs)– Malaria recovery rate and time to genetically
determined new infections after treatments
– PK/PD parameters of ivermectin and ACT
3) Livestock ivermectin/endectocide MDA for malaria
control in human population
Design: placebo-controlled, cluster-randomized, double-
blind trial.
Methods: repeated ivermectin/endectocide administra-
tion to the whole peridomestic livestock population liv-
ing around clusters. Doses and frequency determined by
previous studies
Entomological measures:
– Mosquito survival
– Mosquito population structure/size reduction
– Mosquito immigration into clusters
– Entomological inoculation rate
– Vectorial capacity
Parasite measures:
– Sporozoite rates (mosquitoes)
– Plasmodium prevalence/counts
– Molecular force of infection
– NTD and ectoparasite prevalence/intensity in both
animals and humans
Clinical measures:
– Malaria clinical disease incidence as detected by
passive case detection
– Anaemia prevalenceSupportive studies
Numerous studies are needed to fill knowledge gaps
about ivermectin’s effects on Anopheles, Plasmodium
and transmission. Some of these studies may be neces-
sary to complete before embarking in more specific clin-
ical trials, such as those proposed above.Human plasma levels and mosquito mortality
Current estimates of LC50 of ivermectin for mosquitoes
are based on membrane feeding essays [16,28,32]. Simul-
taneous mosquito feeding and measurement of ivermectin
concentration in plasma (capillary and venous blood from
both men and women) can provide data for a correlation
and calculation of in vivo LC50 and time post-treatment
that the anti-mosquito/anti-sporogonic effect lasts. This
crucial information, combined with current knowledge of
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an ideal dosage and spacing of the drug for malaria con-
trol. Implied is the standardization of current assays to
quantify ivermectin in blood from humans and animals
and also the development of sensitive assays to detect and
measure the drug in the midgut of fed mosquitoes.Confirmation of lethal effects across a range of vector
bionomics
The lethal effects of ivermectin on all Anopheles species
tested so far is expected to extrapolate to exophagic and
exophilic vectors, such as Anopheles minimus and Anoph-
eles dirus in South-East Asia, Anopheles darlingi in South
America, and newly identified vectors [61]. However, this
must be confirmed by well-controlled studies, particularly
those assessing effects on wild populations.The effects of current ivermectin MDA programmes on
malaria transmission
Only a few field trials examining the effects of ivermectin
on wild mosquito populations have occurred. They have
taken advantage of ongoing once-per-year anti-helminth
MDA programmes to assess collateral activity against mos-
quito survival or changes in the sporozoite rates [22].
Reductions in mosquito survival [21,23] and parasite trans-
mission from single MDA are expected to be temporary,
and the degree and duration of these reductions must be
thoroughly defined to eventually move to repeat MDA
trials (Definitive studies). Furthermore, effects must be
compared in diverse habitats containing different vectors
and malaria ecologies. In addition to direct anti-mosquito
effects, measures need to be made on expected changes in
Anopheles population structures (as determined by age-
grading), and third-order effects on entomological inocula-
tion rate (EIR), vectorial capacity, the molecular force of
infection, and the malaria reproductive rate (R0).Modelling
Very few transmission models have included ivermectin
[20,23,35]. Current data suggests that the effect of a sin-
gle ivermectin dose administered to some 80% of a vil-
lage’s population could have a profound effect on the
age structure of the local Anopheles population, reducing
transmission for up to three weeks afterwards. Further
models fitted from empirical data will be essential to
help predict ideal ivermectin MDA dosing and fre-
quency, and the effects MDA might have on local mos-
quito population dynamics, Plasmodium transmission,
and human prevalence. Models will be important to pre-
dict changes of the above outcomes based on variables
such as weather, mosquito immigration, MDA compli-
ance and other concurrent vector control measures.Anti-sporogony effects
A recent study [32] has demonstrated that sublethal
ivermectin concentrations affect P. falciparum transmis-
sion by inhibiting sporogony. These data suggest that
ivermectin MDA may reduce transmission for a longer
period than predicted based on anti-mosquito effects
alone, and also enhance ivermectin’s attractiveness to be
used in combination with anti-malarials to prevent re-
sidual transmission and inhibit the spread of anti-
malarial resistance. This study needs confirmation
using wild parasite isolates and with other Anopheles
and Plasmodium species.
Safety and formulation assessments
A single ivermectin MDA with coverage around 80%
disrupts malaria transmission in a community by chan-
ging the structure of the local mosquito population
[22,23]. The effect is longer than expected given the
current drug formulation´s short half-life. Modelling
[23,35] suggests that intermittent repeated administra-
tion would sustain control while minimizing mosquito
and helminth resistance development. However, an alter-
native, single-encounter, long-lasting formulation could
be less costly and more logistically feasible in MDA or
MSAT approaches, and likely superior in individualized
treatments meant to contain the spread of artemisinin-
resistant Plasmodium. While the current ivermectin
formulation should be tested over the short term,
longer-term research should focus on finding a formula-
tion capable of safely maintaining zero-order release for
a period long enough to have a lasting impact on the
malaria reproductive number (R0). Concurrent toxicity
studies must be done and possible interactions with
anti-malarials and other commonly used drugs assessed.
Emerging resistance
Ivermectin is of capital importance for the control of on-
chocerciasis, lymphatic filariasis and for the treatment of
some soil-transmitted helminths. Increasing the expos-
ure of parasites to the drug is likely to lead to resistance
in other parasites and jeopardize the success of control
programmes. Indeed, ivermectin resistance has been
documented in Sarcoptes scabiei in Australia and pos-
sibly in Onchocerca volvulus in Ghana [62]. Ongoing
surveillance must be established in communities where
ivermectin is introduced as a malaria control measure
and plausible methods to delay or reverse resistance ex-
plored. Combination therapy with a second anthelmin-
tic, such as a benzmidazole, might be effective. Likewise,
proper dosing and MDA spacing might delay ivermectin
resistance development in soil-transmitted helminths.
Ivermectin has a mechanism of action unrelated to
that of commonly used insecticides in malaria-endemic
regions. However, there must be early research on the
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ter understanding of the molecular targets of ivermectin
in the mosquito and possible metabolic detoxification
mechanisms that could foster cross-resistance.
Final comments
Available vector control tools are not effective enough to
achieve widespread malaria elimination or eradication,
and innovative approaches are needed. The use of iver-
mectin solves many challenges identified for future vector
control strategies. It is an effective and safe endectocide
that was approved for human use more than 30 years ago.
Recent studies suggest it might become an effective and
complementary strategy in malaria elimination and eradi-
cation efforts; however, intensive research will be needed
to make this a reality.
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